ライフサイエンスコーパス: multiagent

1 The use of a multiagent algorithm was effective for the initial conve

2 The modeling approach we use is a combined multiagent and classifier systems simulation.

3 twork (social and knowledge approach) with a multiagent approach to effect more realistic behavior.

4 ct of n-3 FAs in breast cancer, as part of a multiagent approach under rigorously controlled conditio

5 Randomized multiagent chemoradiotherapeutic trials have been approa

6 Concurrent multiagent chemoradiotherapy can result in organ preserv

7 Patients then received a postsurgical multiagent chemotherapeutic regimen that consisted of hi

8 Multiagent chemotherapeutic regimens in concert with ade

9 Multiagent, chemotherapeutic regimens for children have

10 rates are poor after standard doxorubicin or multiagent chemotherapies.

11 ficantly different 5-yr survival rates after multiagent chemotherapy (62% vs. 26%; P < or = 0.0051),

12 e substantially improved when RT is added to multiagent chemotherapy (IRS-I and II).

13 lder and unfit patients can receive suitable multiagent chemotherapy and be allocated to HCT based on

14 Thus, thalidomide given in combination with multiagent chemotherapy and dexamethasone is associated

15 All patients were given multiagent chemotherapy and most received irradiation (X

16 l removal if resectable, in combination with multiagent chemotherapy and possibly radiation therapy,

17 hat three different approaches of concurrent multiagent chemotherapy and radiation were feasible and

18 ad received at least a lobectomy followed by multiagent chemotherapy and radiotherapy; cohort one inc

19 improved cure fraction by the combination of multiagent chemotherapy and surgery, although we found n

20 evel of myeloma-propagating cells to survive multiagent chemotherapy and to result in relapse.

21 -cell lung cancer who received postoperative multiagent chemotherapy between 18 and 127 days after re

22 Use of consolidative RT after multiagent chemotherapy in DLBCL is decreasing in the mo

23 Foundation studying radiation and concurrent multiagent chemotherapy in patients with locoregionally

24 Multiagent chemotherapy is standard of care for both ped

25 it-course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse

26 In the context of a multiagent chemotherapy protocol comprising high-dose me

27 oma have remained dismal despite intensified multiagent chemotherapy protocols.

28 or less, and received at least one previous multiagent chemotherapy regimen.

29 Second-line therapy typically includes multiagent chemotherapy regimens followed by autologous

30 ing plan regimens, and within the context of multiagent chemotherapy regimens that include alkylating

31 ologous stem cell transplant or two previous multiagent chemotherapy regimens, and for patients with

32 % improved to 65% to 70% after the advent of multiagent chemotherapy regimens.

33 Both groups were more likely to receive multiagent chemotherapy than were older patients (patien

34 ive disease continued to receive 44 weeks of multiagent chemotherapy that incorporated the assigned i

35 The median TTNT for single- or multiagent chemotherapy was only 3.9 months (95% confide

36 enty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with P

37 adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem cell rescue.

38 adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem-cell rescue, we estima

39 e directly compared with a previous study of multiagent chemotherapy without irradiation (Pediatric O

40 cellent prognosis when treated with adjuvant multiagent chemotherapy without RT.

41 Methotrexate-based multiagent chemotherapy without WBRT is associated with

42 Forty-eight patients received multiagent chemotherapy, and 118 were treated with hormo

43 severe granulocytopenia following intensive multiagent chemotherapy, but is associated with worsened

44 ents have a complete therapeutic response to multiagent chemotherapy, half will relapse, indicating t

45 ge regimens, including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxy

46 9), and ovarian (n= 143) cancer treated with multiagent chemotherapy, of which 233 patients were from

47 n, lower Charlson score, smaller tumor size, multiagent chemotherapy, resection with at least a lobec

48 rlson comorbidity score, smaller tumor size, multiagent chemotherapy, resection with at least a lobec

49 clinical course was aggressive, and despite multiagent chemotherapy, the median survival duration wa

50 mphoblasts isolated from a patient receiving multiagent chemotherapy, this site-specific double-stran

51 microenvironment influences the response to multiagent chemotherapy, we found that stromal Nf1 statu

52 He completed treatment with multiagent chemotherapy-carboplatin, vincristine, temozo

53 the induction and intensification phases of multiagent chemotherapy.

54 n 50% of the patients are cured with current multiagent chemotherapy.

55 Toxicity was greater with multiagent chemotherapy.

56 (95% CI, 0.9-1.3 years) for those receiving multiagent chemotherapy.

57 All but two patients received multiagent chemotherapy.

58 Therapy included multiagent chemotherapy; local control was achieved by r

59 We report on a multiagent computational model of this society that clos

60 roups, organizations, and societies by using multiagent computational models composed of collections

61 In younger adults with AML, multiagent consolidation using mitoxantrone and amsacrin

62 th three cycles of 18 g/m(2) (3x HD-AraC) or multiagent consolidation with two cycles of mitoxantrone

63 erapy using total body irradiation (TBI) and multiagent, high-dose chemotherapy.

64 This approach was investigated using a multiagent imaging protocol for which patients were imag

65 Prompt administration of multiagent immunochemotherapy regimens is associated wit

66 lopment of alloreactivity despite the use of multiagent immunoprophylaxis.

67 ival and extraocular tissue transplantation, multiagent immunosuppressant therapy, and bioartificial

68 Lifelong multiagent immunosuppression is necessary to control deb

69 atients were assigned to receive 20 weeks of multiagent induction chemotherapy and 4 weeks of radioth

70 or equal to 10(-3) at the end of 4 weeks of multiagent induction chemotherapy now receive intensifie

71 strating the usefulness and complications of multiagent intravitreal chemotherapy is necessary for su

72 ts with invasive breast cancer who underwent multiagent NACT with (n = 49) or without (n = 13) taxane

73 This study shows that multiagent PET is feasible and yields unique and potenti

74 oma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy

75 All patients were refractory to at least one multiagent regimen or had relapsed after achieving a com

76 ogic malignancies both as monotherapy and in multiagent regimens in relapsed/refractory disease as we

77 administered in the setting of hepatectomy, multiagent regimens produced a higher cure rate than sin

78 of action of the drugs used and look at the multiagent regimens recommended for use during pregnancy

79 receive systemic chemotherapy, particularly multiagent regimens, at all stages relative to those wit

80 in patients refractory to other single- and multiagent reinduction therapies.

81 in films capable of administering sustained, multiagent release profiles.

82 release as well as both parallel and serial multiagent release.

83 all center around the issue of learning in a multiagent setting, and specifically the question of whe

84 The adoption of aggressive, multiagent, short-course therapy has markedly improved o

85 Multiagent simulation is discussed as a way to link cult

86 Here we resort to multiagent simulations, where a population of individual

87 phocytes, stroma, and necrosis to generate a multiagent spatial model.

88 The information economy will be the largest multiagent system ever conceived and an integral part of

89 All patients received multiagent systemic chemotherapy and whole-brain irradia

90 n the National Cancer Data Base who received multiagent systemic chemotherapy combined with high-inte

91 administered in association with concomitant multiagent systemic chemotherapy to children younger tha

92 one microenvironment and several single- and multiagent targeted approaches to the treatment of advan

93 PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblas

94 trol 232 +/- 30), while animals treated with multiagent therapy had an average nodule count of 11 +/-

95 atients most likely to benefit from selected multiagent therapy.

96 r efficacy was observed with single-agent or multiagent treatment.

97 patectomy, immunization with single-agent or multiagent vaccine therapy appears equivalent.

98 In the setting of hepatectomy, multiagent vaccine therapy offers an advantage over sing

99 ent) or a combination of RANTES/B7.1/GM-CSF (multiagent) was tested.